Table 2.
Patients’ risk factors.
| Case 1 | Case 2 | Case 3 | ||
|---|---|---|---|---|
| GvHD | Skin (grade II) Intestine (grade III–IV) |
- | - | |
| Immunosuppression (at/shortly before detection of viremia) | Budesonide (9 mg/day) | MMF (2 g/day) Ciclosporin |
||
| Prednisolone (once 250 mg) |
Prednisolone (550 mg in total) |
|||
| MTX (1.5 months before) | ||||
| Rituximab (last application before symptom onset) |
3 applications (12 months before) |
10 + 2 applications (same month as symptom onset, 2 applications afterward) |
- | |
| SCT | Allogenic, unrelated | - | Allogenic, unrelated | |
| Serotherapy | ATG | 1 application | - | 2 applications |
| Alemtuzumab | - | - | - | |
| T-cell-depleted grafts | CD34+-selected stem-cell boost | - | - | |
| Lymphocyte count at symptom onset (per µL) |
246 | 204 | <100 leukocytes |
Abbreviations: ATG—anti-thymocyte globulin; GvHD—graft-versus-host disease; MMF—mycophenolate mofetil; MTX—methotrexate; SCT—stem-cell transplantation.